BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials

• Published in: Journal of antimicrobial chemotherapy Vol. 49; no. 3; pp. 535 - 539
• Main Authors: Wootton, M., Bowker, K. E., Holt, H. A., MacGowan, A. P.
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 01.03.2002; Oxford Publishing Limited (England)
• Subjects: Antibacterial agents; Antibiotics. Antiinfectious agents. Antiparasitic agents; Bacteria, Anaerobic - drug effects; Bacteria, Anaerobic - isolation & purification; Biological and medical sciences; Cephalosporins - pharmacology; Drug Resistance, Bacterial; Lactams - pharmacology; Medical sciences; Penicillins - pharmacology; Pharmacology. Drug treatments; Thienamycins - pharmacology; Cephalosporin derivatives; Sensitivity resistance; Anaerobe; Bacteria; Pyrrolidone derivatives; Antibacterial agent; In vitro; Biological activity; Comparative study
• ISSN: 0305-7453; 1460-2091; 1460-2091
• DOI: 10.1093/jac/49.3.535

The in vitro potency of BAL 9141, a new pyrrolidinone cephalosporin, was tested against non-duplicate strains of anaerobic bacteria. The MIC50 was 1 mg/L against Actinomyces species, Clostridium species, Gram-positive anaerobic cocci, Porphyromonas species, Fusobacterium species, Lactobacillus species, Prevotella species and Veillonella species. The MIC50 was 16 mg/L for Bacteroides fragilis and other Bacteroides species. BAL 9141 was not active against cefoxitin-resistant Bacteroides fragilis.